ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stock News for Merck (MRK)
DateTimeHeadline
02/26/201712:30:00Merck’s Letermovir, an Investigational Antiviral Medicine for P...
02/24/201716:00:00In First Phase 3 Trial, Merck’s Investigational Inactivated V...
02/24/201708:32:00Merck Receives Positive CHMP Opinion for New Pergoveris® Fertility...
02/23/201717:12:05Current Report Filing (8-k)
02/16/201708:00:00Merck’s Fight Against Infectious Disease Goes Digital with L...
02/15/201711:31:17Statement of Changes in Beneficial Ownership (4)
02/14/201719:06:00Merck Stops Clinical Trial of Alzheimer's Drug
02/14/201717:00:00Merck Announces EPOCH Study of Verubecestat for the Treatment...
02/14/201716:05:00Merck’s Doravirine, an Investigational Non-Nucleoside Reverse T...
02/13/201717:08:16Statement of Ownership (sc 13g)
02/11/201703:02:00Reckitt Agrees to Mead Deal -- WSJ
02/10/201708:56:41Amended Statement of Ownership (sc 13g/a)
02/10/201708:22:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 4th...
02/10/201706:25:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 3rd...
02/10/201704:21:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 2nd...
02/09/201712:53:39Statement of Changes in Beneficial Ownership (4)
02/09/201710:45:53Schedule 13g
02/09/201709:00:00Merck Foundation Announces Six Program Grant Recipients for Alliance...
02/07/201719:01:00Gilead Posts Profit, Revenue Declines -- Update
02/07/201717:31:00Gilead Posts Profit, Revenue Declines

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US